Concepedia

Publication | Closed Access

Anemia associated with pegylated interferon-?2a and ?2b therapy in hemodialysis patients

DOI

26

Citations

0

References

2007

Year

M. Espinosa, María Dolores Arenas, M.D. Aumente, Guillermina Barril, Juan Manuel Buades, Beatriz Avilés, Diana Carretero, M. Antonia Álvarez-Lara, Fernando Carnicer, A.M. Malo,
Clinical Nephrology

Abstract

In summary, patients treated with PEG-IFN-alpha2a have a major inhibitory effect on erythropoiesis. This could be explained by the different pharmacokinetic properties of PEG-IFN-alpha2a and alpha2b. Further studies are needed to clarify how these findings influence the efficacy, safety and cost-effectiveness of the PEG-IFN-alpha2.